(“Reta/GLP3/Pep3")has been the subject of ongoing clinical investigation for obesity and metabolic research applications.

Published studies and research observations have described:

• Significant reductions in body weight
• Reduced appetite and caloric intake
• Improvements in glycemic markers and HbA1c
• Positive changes in liver fat and metabolic health markers

In Phase 2 clinical research involving obesity and type 2 diabetes, investigators observed clinically meaningful reductions in HbA1c and body weight across multiple dosing groups.

Additional liver-focused research demonstrated substantial reductions in liver fat content in participants with fatty liver disease (NAFLD/MASLD). In one substudy, many participants receiving higher-dose retatrutide no longer met criteria associated with fatty liver disease following the research period.

Researchers have also observed improvements in:

• Insulin sensitivity
• Lipid profiles
• Metabolic biomarkers
• Body composition and fat mass distribution

Community research discussions commonly describe:

• Appetite suppression
• Increased satiety
• Progressive body composition changes
• Improved adherence to calorie-controlled protocols

Research observations are anecdotal and are not clinical claims. Results may vary. Products are intended strictly for laboratory research use only.

Published Research Sources

• PubMed
• NIH / NCBI
• New England Journal of Medicine
• The Lancet
  

  Research Use Only

  Not for human consumption.
  Not intended to diagnose, treat, cure, or prevent any disease.